Peptide profile
Dulaglutide
Long-acting GLP-1 receptor agonist
Compare Dulaglutide with other peptides →Summary
A weekly shot that helps with diabetes and weight loss.
- Typical dose
- 0.75-1.5mg Once weekly
- Route
- Subcutaneous
- Cycle length
- Ongoing
- Evidence
- Limited human data
Mechanism
How it works
Dulaglutide is like a weekly 'set it and forget it' appetite control — one injection works all week long to control hunger and blood sugar.
Dulaglutide is a GLP-1 receptor agonist fused to an Fc fragment of human IgG4 for extended half-life (~5 days), activating GLP-1 receptors throughout body.
Reported in research
Benefits
- You only need one shot each week
- Helps lower your blood sugar a lot
- Helps you lose weight (about 3-5 kg)
- Good for your heart
Context, not a prescription
Dosing
- Typical range
- 0.75-1.5mg Once weekly (Subcutaneous)
- Cycle length
- Ongoing
Safety
Side effects & contraindications
Possible side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Pancreatitis
- Gallstones
- Severe GI events
Contraindications
- Medullary thyroid carcinoma history
- MEN-2
- Pregnancy or breastfeeding
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
You feel less hungry, lose weight, and have better blood sugar.
How it works
Dulaglutide is like a weekly 'set it and forget it' hunger helper. One shot works all week to control hunger and blood sugar.
It turns on GLP-1 switches in your pancreas, brain, and gut. It makes your stomach empty slower and lowers a sugar-raising signal.
What to expect
You feel less hungry within 1-2 days. You lose the most weight by 6 months.
- Week 1: You start to feel less hungry.
- Weeks 4-8: You slowly start losing weight.
- Weeks 12-24: Your blood sugar gets much better and you lose the most weight.
Good to know
- Start with a small 0.75mg dose
- Slowly take a little more over time
- Watch out for bad belly pain
Staying safe
- Feeling sick to your stomach
- Loose poop
- Throwing up
- Belly pain
Avoid if you have:
- People who had a certain thyroid cancer
- People with a condition called MEN-2
- People who are pregnant or breastfeeding
Mechanism of action
Dulaglutide is a GLP-1 receptor agonist fused to an Fc fragment of human IgG4 for extended half-life (~5 days), activating GLP-1 receptors throughout body.
Binds and activates GLP-1 receptors on pancreatic beta cells, neurons, and gut; slows gastric emptying and reduces glucagon secretion.
Pharmacodynamics
Appetite suppression within 24-48 hours; peak weight loss at 6 months.
Reduced appetite, weight loss, improved glycemic control.
Timeline
- Week 1: Initial appetite reduction.
- Weeks 4-8: Progressive weight loss.
- Weeks 12-24: Maximum HbA1c improvement and weight reduction.
Comparisons
- Dulaglutide — effectiveness High, safety Good, cost $$$, Very Easy to use
- Semaglutide — effectiveness Very High, safety Good, cost $$$, Very Easy to use
Adverse effects
Common:
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
Rare:
- Pancreatitis
- Gallstones
- Severe GI events
Contraindications & risk mitigation
Contraindicated in:
- Medullary thyroid carcinoma history
- MEN-2
- Pregnancy or breastfeeding
- Start at 0.75mg
- Gradual dose escalation
- Monitor for severe abdominal pain
Qué hace
Sientes menos hambre, pierdes peso y tienes mejor control del azúcar en sangre.
Cómo funciona
La dulaglutida es como un ayudante del hambre semanal de 'ponerlo y olvidarlo'. Una inyección funciona toda la semana para controlar el hambre y el azúcar en sangre.
Activa los interruptores del GLP-1 en tu páncreas, cerebro e intestino. Hace que tu estómago se vacíe más despacio y reduce una señal que sube el azúcar.
Qué esperar
Sientes menos hambre en 1-2 días. Pierdes más peso a los 6 meses.
- Semana 1: Comienzas a sentir menos hambre.
- Semanas 4-8: Comienzas a perder peso poco a poco.
- Semanas 12-24: Tu azúcar en sangre mejora mucho y pierdes la mayor cantidad de peso.
Bueno saber
- Comenzar con una dosis pequeña de 0.75mg
- Aumentar un poco la dosis gradualmente con el tiempo
- Estar atento a dolores de barriga fuertes
Manteniéndose seguro
- Sentirse con náuseas
- Heces sueltas
- Vómitos
- Dolor de barriga
Evitar si tienes:
- Personas que han tenido cierto tipo de cáncer de tiroides
- Personas con una condición llamada MEN-2
- Personas que están embarazadas o en periodo de lactancia
Mecanismo de acción
La dulaglutida es un agonista del receptor GLP-1 fusionado con un fragmento Fc de IgG4 humana para prolongar su vida media (~5 días), activando los receptores GLP-1 en todo el cuerpo.
Se une y activa los receptores GLP-1 en las células beta pancreáticas, neuronas e intestino; ralentiza el vaciado gástrico y reduce la secreción de glucagón.
Farmacodinamia
Supresión del apetito en 24-48 horas; pérdida máxima de peso a los 6 meses.
Apetito reducido, pérdida de peso y mejor control glucémico.
Cronología
- Semana 1: Reducción inicial del apetito.
- Semanas 4-8: Pérdida de peso progresiva.
- Semanas 12-24: Mejora máxima de la HbA1c y reducción de peso.
Comparaciones
- Dulaglutida — efectividad Alta, seguridad Buena, costo $$$, Muy fácil de usar
- Semaglutida — efectividad Muy alta, seguridad Buena, costo $$$, Muy fácil de usar
Efectos adversos
Comunes:
- Náuseas
- Diarrea
- Vómitos
- Dolor abdominal
Raros:
- Pancreatitis
- Cálculos biliares
- Eventos gastrointestinales graves
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Antecedentes de carcinoma medular de tiroides
- MEN-2
- Embarazo o lactancia
- Comenzar con 0.75mg
- Aumento gradual de la dosis
- Vigilar dolor abdominal grave
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- Ongoing
FAQ
Common questions
How does it compare to semaglutide?
Semaglutide has superior weight loss; dulaglutide is still effective but less potent.
Can I miss a dose?
If missed within 3 days, take it; if more than 3 days, skip and resume next scheduled.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Dulaglutide is rated as Limited human data. Limited human data is available.
- 1. AWARD trial dulaglutide (2016) — DOI:10.2337/dc16-0057
- 2. REWIND cardiovascular (2019) — DOI:10.1016/S0140-6736(19)31149-3
- 3. AWARD trial dulaglutide (2016)
- 4. REWIND cardiovascular (2019)